Are ipamorelin and sermorelin the same thing?

No. Sermorelin is a GHRH analogue; ipamorelin acts at the ghrelin receptor. They engage different pathways and sit in different regulatory positions.

Are they FDA-approved?

Sermorelin was previously approved and later withdrawn as a branded product; it is still compounded. Ipamorelin has been placed in the FDA category of bulk substances raising significant safety concerns for compounding.

Can they be combined?

Combinations are discussed in this field, but whether any combination is appropriate is a clinical judgement, not something to arrange from a forum post.

Will they show up on a drug test?

Both fall within the WADA prohibited list covering peptide hormones and growth factors. Assume yes if you compete under a testing body.

Ipamorelin vs sermorelin

These two get discussed together constantly, and they are not the same kind of thing. Sermorelin is an analogue of growth hormone-releasing hormone. Ipamorelin works through a different receptor entirely, mimicking ghrelin. Both are discussed in the context of the body's own growth hormone signalling, but they arrive there by different routes.

Their regulatory positions differ sharply too, which matters more in practice than the mechanism does.

SermorelinGHRH analogue
IpamorelinGhrelin receptor agonist
BothPrescriber-directed only
SportWADA-prohibited

Different receptors, different routes

Sermorelin corresponds to the active fragment of growth hormone-releasing hormone — the signal the hypothalamus sends the pituitary. It engages the GHRH receptor.

Ipamorelin is a growth hormone secretagogue acting at the ghrelin receptor, a separate pathway that also feeds into pituitary signalling. It is described as selective, meaning it is characterised as engaging that pathway without the broader hormonal effects some earlier secretagogues showed.

What research explores is how these pathways interact and what stimulating either does over time. That literature is not settled, and this page is not the place to pretend otherwise.

Regulatory status — the practical difference

Sermorelin was previously approved as a medicine in the United States and was subsequently withdrawn from the market as a branded product. It continues to be prepared by compounding pharmacies and prescribed by clinicians who work in this area.

Ipamorelin's position is different and more restrictive. The FDA placed it in the category of bulk substances that raise significant safety concerns for use in compounding, which constrains lawful preparation considerably.

Both are prohibited in competitive sport under the World Anti-Doping Agency's rules covering peptide hormones and growth factors. If you compete under a testing body, that is decisive regardless of anything else on this page.

What a course involves

There is no published list price for either in the way there is for a branded pharmaceutical, so we do not print one. Cost, where a clinician is involved, is usually a combination of the consultation, any laboratory work, and the pharmacy preparation itself.

Material sold online for research use is a different category entirely. It is not prepared to pharmaceutical standards and is not intended for human use, whatever the accompanying marketing implies.

How to approach this

Start with what you are actually trying to address and get it investigated properly. Growth hormone signalling can be measured, and a clinician who works in this area will want laboratory results before discussing anything.

Dosing is determined by a licensed provider. Any protocol you find circulating online was not written for you.

How we verify providers

Questions

Ipamorelin vs sermorelin: common questions

Are ipamorelin and sermorelin the same thing?: No. Sermorelin is a GHRH analogue; ipamorelin acts at the ghrelin receptor. They engage different pathways and sit in different regulatory positions.
Are they FDA-approved?: Sermorelin was previously approved and later withdrawn as a branded product; it is still compounded. Ipamorelin has been placed in the FDA category of bulk substances raising significant safety concerns for compounding.
Can they be combined?: Combinations are discussed in this field, but whether any combination is appropriate is a clinical judgement, not something to arrange from a forum post.
Will they show up on a drug test?: Both fall within the WADA prohibited list covering peptide hormones and growth factors. Assume yes if you compete under a testing body.

Talk to a licensed provider before considering either

Peptides in this category are prescriber territory. We connect you with licensed providers who can investigate what is actually going on and tell you whether any of this is appropriate.

Find a licensed provider

TreatRadar is an information and referral service. We are not a medical provider, we do not practise medicine, and nothing here is medical advice, diagnosis, or a treatment recommendation. Decisions about treatment belong to you and a licensed clinician who knows your history.

We may be compensated when you connect with a provider through this site. That never changes which providers we list or how we describe them — how we verify providers.

Some information (pricing, provider coverage, state rules) may change or await verification — confirm details directly with the provider or the relevant state medical board before booking.